Kardigan filed for a Nasdaq IPO to raise about $320 million, targeting cardiovascular indications spanning genetic dilated cardiomyopathy and calcific aortic valve stenosis. The company plans to finance multiple late-stage programs, including danicamtiv in a phase 2b/3 program and ataciguat for CAVS, and is also budgeting for tonlamarsen, a liver-directed antisense for hypertension. The filing highlights how developers are using public markets to consolidate exposure across related cardiac mechanisms rather than single-asset bets. If priced and underwritten as expected, it would mark another major step for late-stage cardio biotech funding alongside recent large IPO activity.